CAJ | 학술논문

目的：观察常规剂量替罗非班联合半剂量瑞替普酶在ST 段抬高性急性心肌梗死中的溶栓效果与安全性。方法选取2011年1月至2013年3月于该院进行治疗的60例S T段抬高性急性心肌梗死患者，分为瑞替普酶组（对照组，n＝32）和替罗非班联合瑞替普酶组（观察组，n＝28），比较两组患者不同时间的梗死相关血管再通率、并发症发生率。结果观察组不同时间梗死相关血管再通率均高于对照组（P＜0．05），两组并发症发生率差异无统计学意义（P＞0．05）。结论常规剂量替罗非班联合半剂量瑞替普酶在ST段抬高性急性心肌梗死中的溶栓效果较佳，且不增加并发症发生率。
목적：관찰상규제량체라비반연합반제량서체보매재ST 단태고성급성심기경사중적용전효과여안전성。방법선취2011년1월지2013년3월우해원진행치료적60례S T단태고성급성심기경사환자，분위서체보매조（대조조，n＝32）화체라비반연합서체보매조（관찰조，n＝28），비교량조환자불동시간적경사상관혈관재통솔、병발증발생솔。결과관찰조불동시간경사상관혈관재통솔균고우대조조（P＜0．05），량조병발증발생솔차이무통계학의의（P＞0．05）。결론상규제량체라비반연합반제량서체보매재ST단태고성급성심기경사중적용전효과교가，차불증가병발증발생솔。
Objective To study the thrombolysis effect and safety of tirofiban combined with half dose reteplase in patients with ST segment elevation acute myocardial infarction .Methods 60 patients with ST segment elevation acute myocardial infarction in our hospital from January 2011 to March 2013 were selected as research object ,and they were divided into reteplase group (control group ,n=32) and tirofiban combined with reteplase group (observation group ,n=28) ,then the recanalization rate of infarct-relat-ed artery at different time and incidence of complications were compared .Results The recanalization rate of infarct-related artery of observation group at different time were all higher than those of control group (P<0 .05) ,while incidence of complications of two groups had no significant difference(P>0 .05) .Conclusion The thrombolysis effect of tirofiban combined with half dose reteplase in patients with ST segment elevation acute myocardial infarction is better ,and it does not increase the incidence of complications .